Background: Severe up to life-threatening neuropathy has been observed in patients with hereditary neuropathies receiving vincristine.
A 52-year-old white female was diagnosed with high grade non-Hodgkin's lymphoma (R.E.A.L. Classification: predominantly diffuse/partly follicular large B-cell type) in January 1998. Clinically she presented with bilateral cervical lymphadenopathy, night sweats and subfebrile temperatures. Definite diagnosis was made histologically by lymph node exstirpation. Further diagnostic studies revealed three suspicious pulmonary nodules without any other lymphoma manifestation and she was staged IVB (Ann Arbor Classification). CHOPchemotherapy (total doses: cyclophosphamide 1300 mg, adriamycin 85 mg, vincristine 2 mg, prednisone 170 mg) was given on 22 January 1998 outside hospital. At that point the neurologic status and clinical examination results were reported normal. No family history was obtained. About ten days later the patient started to notice neurologic symptoms as muscular weakness both in the upper and lower extremities (power grade IV), paresthesia of the fingertips, bilateral sensory impairment of feet and lower legs and slight dysphagia. On 13 February, however, a second course of CHOP chemotherapy in the same dosage was initiated. Symptoms worsened significantly resulting in dependency on a wheelchair and inability to perform her work as a painter. Finally she consulted a neurologist and was admitted to hospital for further diagnostic studies and continuation of treatment for her lymphoma in March 1998 with a provisional diagnosis of severe vincristineinduced neuropathy. Medical history at time of admission included hyperthyroidism, that was currently treated with propylthiouracil, a MALT lymphoma 1983, that was treated surgically only, and a meningoencephalitis in 1968. No further medication was taken. In addition she had a history of Lyme disease since 1993 with positive IgM-titer until December 1997, when antibiotic therapy with doxycycline and ceftriaxone was administered successfully. Family history obtained on admission revealed that her mother had non-specific neuropathic symptoms as well as a poorly defined foot deformities of the mother's father. The patient's brother does not show any neurologic impairment and is in good physical health.
Physical examination
The patient was a 52-year-old, white female (61 kg, 165 cm) in poor general physical condition who obviously needed a wheelchair. There were no pathologic findings of heart, lung and abdomen though she had a slight exophthalmic goiter. Eye movement and vision were unremarkable. No palpable lymphadenopathy was found.
The neurologic examination showed marked, especially distal muscular weakness involving the lower more than the upper extremities and the extensor muscles more than the flexors (extension of the knee: power grade (PG) II, extension of the feet: PG III, flexion of knee and feet: PG IV, finger extension: PG III, ability to make fist 25 kpa (right) and 35 kpa (left)). Muscular tone was slightly reduced, and there was muscular atrophy especially in the interosseous, hypothenar, thenar, anterior tibial and in the gastrocnemius muscles and a bilateral pes cavus ( Figure 1 ). The patient had developed areflexia except of the biceps tendon jerks. Babinsky signs were negative and there were no cerebellar signs, meningism or ataxia. The lower extremities in particular demonstrated a sharp and light touch hypoaesthesia and a loss of temperature sense in a stocking glove distribution. Vibration sensation was 5/8 bilaterally both at the wrists and the ankles. Marked paraesthesia of the fingertips was reported. Other findings included dysphagia and bulbar speech.
Diagnostic findings
Laboratory results on admission: Blood count and differential count were within normal limits except for a decreased lymphocyte count (15.5%). Protein electrophoresis, hemostatic parameters and common laboratory results did not show pathologic findings apart from a markedly decreased basal thyroid stimulating hormone. Cerebrospinal fluid revealed no abnormality except for a positive IgG antibody titer for Borrelia burgdorferi. Titer for IgM, however, was negative. The same antibody pattern for Borrelia burgdorferi could be found in the patient's serum. Viral antibody titers for herpes virus, FSME, Epstein-Barr virus as well as the TPHA were nondiagnostic. Imaging studies: There were only three pulmonary nodules suspicious for lymphoma on computered tomog- raphy of the lung and brain, abdominal ultrasound, chest X-ray, and cerebral MRI.
Electrophysiological studies: Nerve conduction velocity (NCV) of the motoric nerves was markedly decreased in general, and there was massive impairment of sensory nerve function (ulnar and median nerve: NCV 20 m/s, no F-wave, no SNAPs; peroneal nerve and tibial nerve: NCV not reproducable, no EMAPs, no F-wave). Electromyography showed increased acute muscle denervative activity and reduction of compound muscle action potentials (anterior tibial muscle).
Histopathologic findings: biopsy of the sural nerve and the anterior tibial muscles demonstrated hypertrophic and fibrotic changes of nerve myelination as well as axonal degeneration and focal atrophy of muscle fibers. No lymphocellular muscle infiltration was seen (Figures 2 and 3) .
Clinical course
Clinical, electrophysiologcial and histological findings were suggestive of a demyelinating and axonal degener-ative neuropathy as seen in hereditary motor and sensory neuropathies (HMSNs). However, the onset of neurologic symptoms coincided with the administration of vincristine. Therefore, further diagnostic studies were performed to look for an underlying hereditary or chronic neurologic disease and molecular genetic analysis revealed 17pll.2 duplication typical for CharcotMarie-Tooth disease type IA.
Treatment for lymphoma was continued using regimens without vincristine (CHED (cyclophosphamide, adriamycin, VP 16, dexamethasone), Dexa-BEAM (dexamethasone, BCNU, VP 16, cytarabine, melphalan) and trophosphamide (idarubicin) resulting in very good temporary response. Neurologic symptoms slowly recovered over a time period of six months and on her last visit the patient was able to perform her work as a painter and to walk again. Physical examination demonstrated improved muscular strength of both upper and lower extremity (power grade IV-V) and only little residual sensory impairment of the finger tips and of the forefoot. Chemotherapy is still continuing.
Discussion
We described a case of acute deterioration of CharcotMarie-Tooth disease (CMT) IA following 4 mg of vincristine in a 52-year-old white female, leading from initally missing clinical symptoms to finally incomplete tetraparesis. Charcot-Marie-Tooth disease was reported in 1886 for the first time by Charcot and Marie (Paris, France) [1] and Tooth (Cambridge, Great Britain) [2] and today represents a heterogenous group of disorders of peripheral nerve, that is characterized by progressive weakness and atrophy of distal muscles, loss of tendon reflexes, mild sensory impairment and foot deformity (pes cavus, hammertoes). Originally, this group was classified as hereditary motor and sensory neuropathies. In summary the population prevalence of all types of CMT is approximately 1 in 2500. Symptoms usually occur within the second life decade, but also sometimes up to the age of 40 and in general show a benign and chronic clinical course. Besides extensive physiotherapy and the use of anabolics there is no effective prevention or treatment known.
Two major types of CMT can be differentiated both by nerve conduction velocity (NCV) and histologic and genetic findings. CMT type I is characterized by reduced or slowed NCV (usually < 38 m/s), 'onion bulbs' consisting of defective Schwann cell processes and a hypertrophic demyelinating peripheral neuropathy, that sometimes clinically presents in a palpable major auricle nerve [3] [4] [5] . In contrast, CMT type II, which is also called the neuronal form of CMT, has normal to minimal slowed NCV and pathological evidence of axonal degeneration [3, 4] . Both types are inherited in an autosomal dominant pattern with an incidence of spontaneous mutations in 20% of cases. About 60% of all patients with CMT suffer from the demyelinating type I. This group further can be devided into type IA (70%), type IB (20%) and type IC (10%), which only vary genetically and do not show significant clinical or electrophysiological differences. Type IA maps to chromosome 17pl 1.2 and is caused in the majority of cases by a duplication of 1.5 Mb DNA, encompassing the peripheral myelin protein 22 (PMP22) gene, resulting in overexpression of PMP22 [6] [7] [8] [9] [10] . Synthesis of a defective PMP22 is usually based on spontanenous point mutation within the PMP22 gene [11] . Type IB maps to chromosome lq21-23 and is accounted for by point mutation in the myelin protein zero (Po) gene [12] . The gene locus for type IC is not known. Some other rare types of CMT include Dejerine-Sottas syndrome (DSS), which was originally described as CMT type III and is characterized by extremely decreased NCV (< 10 m/s) and an early clinical onset in childhood and a severe clinical course [3, 5] . Nowadays usually DSS is interpreted as a subtype of CMT type I. A heterogenous group of autosomal recessive forms of CMT is called CMT IV and another group, that consists either of the dominant connexin-32 gene (Xql3.1) linked types or of the recessive types of X-linked CMT, is defined as CMTX [10, 13, 14] .
Vincristine is known to be an antitumor agent of the class of the vinca alkaloids with dose-limiting neurotoxicity. By binding and inactivation of tubulin it disrupts microtubule function in neuronal axons and, therefore, inhibits axoplasmatic transport, which leads to axonal degeneration as shown by histologic findings and nerve conduction velocity studies [15, 16] . Neurotoxicity from vincristine is both an individual-dose and a cumulative-dose phenomenon. Initial symptoms usually are paresthesias of the distal extremities, especially of the fingertips, and impairment of deep tendon reflexes. Sometimes muscle weakness and paralysis as well as cranial nerve involvement occurs. As in CMT there is no effective prevention or therapy known except for immediately stopping giving vincristine, physiotherapy and waiting for clinical recovery.
As shown in our patient the coincidence of vincristine use and underlying CMT IA can lead to severe neurologic impairment even after only a small dose of vincristine. If these symptoms are unusually impressive or do not recover before the next course of vincristine, diagnostic work-up for underlying hereditary neuropathy including nerve conduction velocity studies and sometimes molecular genetic analysis shoud be performed. No further use of vincristine or at least adequate dose reduction have also to be considered. Otherwise, consequences can be as deleterious for the quality of life as seen in the presented patient having received a second course of 2 mg of vincristine.
In CMT IA the overexpression of transmembrane protein PMP22, that plays an essential role in myelin integrity and cellular growth [17] , may result in prevention of Schwann cell differentiation after myelination has been initiated, followed by apoptosis [18, 19] . An increased proportion of PMP22 within in the cell membrane may also impair the structural integrity of the myelin and cause its degeneration. As macrophage mediated myelin degneration has a mitogenic effect on Schwann cells and increases proliferation rate, remyelination occurs [20] . The histologic findings in our case showing both hypertrophic and fibrotic changes of the nerve myelination as well as axonal degeneration, therefore, demonstrate typical signs both seen in CMT IA and in axonal degeneration caused by vincristine. As there is a linear correlation between axon loss and clinical symptoms [21] , vincristine probably has an extensive effect on axonal degeneration in patients with CMT IA compared to those without an underlying chronic neuropathic disease, that results in severe neurologic impairment as observed in our patient. However, only a few cases like ours, including one with a fatal outcome due to respiratory failure, have been reported [22] [23] [24] [25] [26] . This might either be explained by a statistically low risk of suffering from CMT IA and getting vincristine chemotherapy, but can also be based on a number of patients suffering from severe vincristine induced neuropathy, that were never diagnosed for CMT IA.
Other types of CMT may also predispose for vincristine-related neuropathy. In CMT IB defects in the myelin protein zero, a major integral myelin membrane protein stabilizing the cell membrane and also mediating membrane adhesion in the concentric myelin wraps [27, 28] , also lead to axonal degeneration. Neuropathic symptoms, however, seem to be more moderate and patients suffering from CMT IB may be less sensitive to the neurotoxic effect of vincristine than in CMT IA [25] . Furthermore, axon loss is observered in the dominant types of CMTX, where mutations in the gap junction protein connexin 32 gene results in improper gating abilities of the connexin hemichannels [13, 29, 30] . Though this also suggests a certain sensitivity to vincristine, no case has yet been reported. There also have been no reports on other chemotherapeutic drugs as e.g., cisplatin and paclitaxel/docetaxel with well known neurotoxic potential for conincident neurologic deterioriation in any type of CMT.
Summary: As there is an obvious predisposition for severe neuropathy secondary to vincristine in patients with CMT IA and a possible predisposition in other types of hereditary neuropathies as well as a presumable risk for other toxic neuropathies in all types of CMT [31] , a detailed family history and careful clinical examination should be obtained before exposing patients to any kind of neurotoxic agents. When chemotherapeutic regimens include vincristine it seems to be important to look for Charcot-Marie-Tooth disease and to determine, whether this regimen can be used safely. In those cases suggestive of CMT before starting vincristine chemotherapy and in patients who have already developed unusually severe neurologic symptoms after one or two courses of vincristine, pretherapeutic electrophysiological studies including nerve conduction velocities (NCV) of at least one motor and one sensory nerve should be performed routinely, as decreased NCVs can be seen early in the clinical course of CMT long before the onset of clinical symptoms. If then indicated, DNA testing for the PMP22 gene followed by testing for P0 and connexin 32 should follow [32] [33] [34] .
Conclusion: Vincristine is a well known risk factor for acute deterioration of Charcot-Marie-Tooth disease and can result in life-threatening neuropathy in some patients. Therefore, careful clinical screening for underlying hereditary motor and sensory neuropathy should be performed in advance and also in cases suggestive of CMT due to their clinical course. Besides medical history and physical examination nerve conduction velocity studies have been shown to be a valuable tool in the assessment of CMT disease and related neuropathies [21] . However, final diagnosis of CMT and its subtypes can only be done by molecular genetic analysis. Though in case of CMT IB a cautious use of vincristine may be considered [25] , in CMT IA patients it should not be given at all.
